Predictive Oncology (NASDAQ:POAI) Receives Neutral Rating from HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Predictive Oncology (NASDAQ:POAI) in a report issued on Friday, Marketbeat Ratings reports. HC Wainwright also issued estimates for Predictive Oncology’s Q4 2025 earnings at $0.06 EPS, FY2026 earnings at $0.08 EPS, FY2027 earnings at $0.27 EPS and FY2028 earnings at $0.46 EPS.

Predictive Oncology Stock Down 0.7 %

POAI stock opened at $0.68 on Friday. The company has a 50 day moving average of $0.75 and a two-hundred day moving average of $1.05. The company has a market cap of $4.54 million, a price-to-earnings ratio of -0.22 and a beta of 1.14. Predictive Oncology has a 12-month low of $0.55 and a 12-month high of $3.76.

Predictive Oncology Company Profile

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.